CNS Pharmaceuticals Q3 net loss narrows as R&D costs fall

By Reuters News


Overview

  • US biotechnology firm reported Q3 net loss narrowed yr/yr as R&D expenses declined

  • Company's general and administrative expenses rose on higher consulting and personnel costs

  • Company aims to complete first pipeline-building transaction by year-end 2026


Outlook

  • CNS Pharmaceuticals aims to complete its first pipeline-building transaction by year-end 2026

  • Company is in advanced discussions to acquire or license new therapeutic assets

  • Future R&D expenses will depend on timing and nature of any acquired assets


Result Drivers

  • LOWER CLINICAL COSTS - R&D expenses fell due to lower clinical costs for Berubicin after completion of enrollment and patient treatments, and reduced TPI 287 manufacturing costs

  • HIGHER BUSINESS DEVELOPMENT COSTS - General and administrative expenses rose mainly due to higher consulting expenses related to business development and increased personnel-related costs


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$0.24

Q3 Net Loss

$2.5 mln


Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for CNS Pharmaceuticals Inc is $10.00, about 246% above its November 13 closing price of $2.89


Reuters Recommended Reads

  • Nov 16 - Prelude Therapeutics Q3 net loss narrows as expenses fall

  • Nov 13 - PDS Biotechnology Q3 net loss narrows on lower R&D costs

  • Nov 16 - Larimar Therapeutics Q3 net loss narrows as R&D expenses fall


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.